Intranasal Delivery of Cationic PLGA Nano/Microparticles- Loaded FMDV DNA Vaccine Encoding IL-6 Elicited Protective Immunity against FMDV Challenge

Wang, Gang; Pan, Li; Zhang, Yongguang; Wang, Yonglu; Zhang, Zhongwang; Lu, Jianwei; Zhou, Peng; Fang, Yuqi; Jiang, Shoutian

doi:10.1371/journal.pone.0027605

Cited by 60 publications

(45 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, studies have focused on the use of cytokines as intranasal vaccine adjuvants to enhance the immunogenicity of the DNA vaccine because of their potent effects on innate and adaptive immunity as well as functional diversity of immune responses. Studies have shown that cytokines, such as IL-12 [13,14] , IL-2 [15] , IL-15 [16] , type I interferon (IFN) [17,18] , IL-1 [19] , IL-6 [20] , and granulocyte-macrophage colony-stimulating factor (GM-CSF) [21] , enhanced antigen-specific immunity following delivery with different antigens.…”

Section: Introductionmentioning

confidence: 99%

“…IL-6 effectively functions as a mucosal adjuvant that significantly enhances the mucosal and systemic immune responses [20,27] . DNases present at mucosal surfaces can easily degrade the DNA vaccination plasmid used to stimulate mucosal immunity.…”

Section: Introductionmentioning

confidence: 99%

“…DNases present at mucosal surfaces can easily degrade the DNA vaccination plasmid used to stimulate mucosal immunity. However, the presence of IL-6 as a vaccine adjuvant can significantly elicit both the mucosal and systemic immune responses, which provides a method of stimulating mucosal immunity with the combined DNA plasmid and il-6 gene [20,28] . In vivo studies have shown that IL-6 plays a critical role in the development of mucosal IgA antibody responses, which acts as the first line of the host immune defense and is critical for the protection of mucosal tissues [29] .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine

et al. 2014

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To investigate the effects of co-delivering IL-6 expressing plasmid pCI-IL-6 on the immunogenicity of the anti-caries DNA vaccine pCIA-P, which encodes the surface protein antigen PAc of Streptococcus mutans. Methods: Plasmid pCI-IL-6 was constructed by inserting the murine IL-6 gene into the pCI vector. Expression of IL-6 in vitro was assessed using Western blot analysis. BALB/c mice were intranasally co-immunized with pCIA-P plus pCI-IL-6 on d 0 and 14. Anti-PAc IgG and secretory IgA (sIgA) were assessed by ELISA. Splenocytes from the mice were re-stimulated with the PAc protein, and IFN-γ and IL-4 production was measured using ELISA. Splenocyte proliferation was analyzed with flow cytometry. Rats were similarly immunized, and dental caries scores were determined using the Keyes method. Results: Marked expression of IL-6 was found in COS-7 cells transfected with pCI-IL-6. In the pCI-IL-6 co-immunized mice, the specific IgG antibodies in serum and sIgA antibodies in saliva were significantly higher than those in the control mice at weeks 4 and 8. Moreover, the secretion of IFN-γ from splenocytes in response to re-stimulation with PAc protein was significantly higher in the pCI-IL-6 co-immunized mice than that in the control mice, whereas the secretion of IL-4 had no significant difference. The proliferation of splenocytes from the pCI-IL-6 co-immunized mice was significantly higher than that from the mice immunized with pCIA-P and pCI vector. In the rat caries model, the pCI-IL-6 co-immunization rats displayed lower caries scores than the control rats. Conclusion: Intranasal co-delivery of IL-6 gene significantly enhances the immunogenicity of the anti-caries DNA vaccine.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine

et al. 2014

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…After 48-hour transfection, cells were harvested and analyzed for expression of FMDV P12A3C by indirect immunofluorescence test. Cell monolayers were cultured on cover slips and fixed The Chi-PLGA-DNA nanoparticles were prepared using an emulsion-diffusion-evaporation method as previously described, 32,35 except that a microball mill (Pulverisette ® 7; Fritsch GmbH, Idar-Oberstein, Germany,) was used to reduce particle size. Nanoparticles were stored at 4°C.…”

Section: Preparation Of the Chi-plga-dna Nanoparticlesmentioning

confidence: 99%

“…We demonstrated that intranasal delivery of nanoparticles loaded with FMDV DNA vaccine formulations encoding interleukin 6 (IL-6) as a molecular adjuvant enhanced protective immunity against FMDV. 32 Other reports obtained potent nasal mucosal and systemic immune responses using intranasal delivery of whole, inactivated influenza vaccine powder formulations. Powder-formulated vaccine elicited a significant serum antibody response in rats that was at least as strong as the response from liquid vaccine administered by intranasal route or by intramuscular injection.…”

mentioning

confidence: 99%

Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles

Pan¹,

Zhang²,

Lv³

et al. 2014

IJN

Self Cite

View full text Add to dashboard Cite

The aim of this study was to enhance specific mucosal, systemic, and cell-mediated immunity and to induce earlier onset of protection against direct-contact challenge in cattle by intranasal delivery of a nanoparticle-based nasal vaccine against type A foot-and-mouth disease (FMD). In this study, two kinds of nanoparticle-based nasal vaccines against type A FMD were designed: (1) chitosan-coated poly(lactic-co-glycolic acid) (PLGA) loaded with plasmid DNA (Chi-PLGA-DNA) and (2) chitosan-trehalose and inactivated foot-and-mouth disease virus (FMDV) (Chi-Tre-Inactivated). Cattle were immunized by an intranasal route with nanoparticles and then challenged for 48 hours by direct contact with two infected donor cattle per pen. Donors were inoculated intradermally in the tongue 48 hours before challenge, with 0.2 mL cattle-passaged FMDV. Serological and mucosal antibody responses were evaluated, and virus excretion and the number of contact infections were quantified. FMDV-specific secretory immunoglobulin (Ig)A (sIgA) antibodies in nasal washes were initially detected at 4 days postvaccination (dpv) with two kinds of nanoparticles. The highest levels of sIgA expression were observed in nasal washes, at 10 dpv, from animals with Chi-PLGA-DNA nanoparticles, followed by animals immunized once by intranasal route with a double dose of Chi-Tre-Inactivated nanoparticles and animals immunized by intranasal route three times with Chi-Tre-Inactivated nanoparticles ( P <0.05). FMDV-specific IgA antibodies in serum showed a similar pattern. All animals immunized by intranasal route developed low levels of detectable IgG in serum at 10 dpv. Following stimulation with FMDV, the highest levels of proliferation were observed in splenocytes harvested from Chi-PLGA-DNA-immunized animals, followed by proliferation of cells harvested from Chi-Tre-Inactivated nanoparticle-immunized animals ( P <0.05). Higher protection rates were associated with the highest sIgA antibody responses induced in the Chi-PLGA-DNA nanoparticle-immunized group. Only one animal was clinically affected with mild signs after 7 days of contact challenge, after a delay of 2–3 days compared with the clinically affected negative-control group. Of the five animals directly challenged that were vaccinated by intranasal route with a double dose of Chi-Tre-Inactivated, four were clinically infected; however, the degree of severity of disease in this group was lower than in control cattle. The number of viral RNA copies in nasal swabs from the vaccinated, severely infected group was significantly higher than in swabs from the vaccinated, clinically protected group. These data suggested that intranasal delivery of Chi-PLGA-DNA nanoparticles resulted in higher levels of mucosal, systemic, and cell-mediated immunity than did of Chi-Tre-Inactivated nanoparticles. In conclusion, although intranasal delivery with FMDV antigen mediated by nanoparticles did not provide complete clinical protection, it reduced disease severity and...

show abstract

Biopolymer‐based Carriers for DNA Vaccine Design

et al. 2021

View full text Add to dashboard Cite

She studied chemistry at the University of Zagreb, and completed her PhD at the University of Strathclyde,G lasgow,w orking on DNA detection by advanced spectroscopies, such as SERRS. After postdoc research on DNA nanostructuring and artificial enzyme design at the University of Dortmund,s he was agroup leader at Karlsruhe Institute of Technology before joining Cambridge. Her research focuses on nanostructured biomaterials for use in photocatalysis and targeted drug delivery.

show abstract

Intranasal Delivery of Cationic PLGA Nano/Microparticles- Loaded FMDV DNA Vaccine Encoding IL-6 Elicited Protective Immunity against FMDV Challenge

Cited by 60 publications

References 42 publications

Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine

Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine

Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles

Biopolymer‐based Carriers for DNA Vaccine Design

Contact Info

Product

Resources

About